Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
2019;173:e192841
Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study
Employers only pay when predefined outcomes are achieved Guaranteed improvements in A1C, weight loss, and deprescription of GLP-1s and other medications ROI is validated using pharmacy and medical claims data Reported outcomes include a 2.2-point average A1C reduction for members with starting A1C greater than8.0 and a 14-pound average weight loss for members with a BMI greater than 30, based on internal data from Twin Healths commercial populations as of September 2024 Demonstrated reductions in diabetes-related pharmacy spend while maintaining clinical appropriateness Precision medication management Employers can start by using claims and clinical data to identify risk levels and guide GLP-1 eligibility
Do you have a question about this product
US$ 26.75
US$ 22.35
US$ 26.79
US$ 23.27
US$ 24.73
US$ 29.71
US$ 24.70
